To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

NCT01069926 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Glucose Lowering

Interventions

DRUG: AZD1656

Sponsor

AstraZeneca